期刊文献+

葡萄球菌肠毒素超抗原广谱抑制性多肽的功能研究 被引量:3

Study on the function of a broad-spectrum inhibitory peptide against SEs superantigen
下载PDF
导出
摘要 目的在前期筛选出针对SEA、SEB、SEC具有广谱抑制性的多肽P72基础上,通过竞争结合实验和动物模型对多肽P72的抑制机制进行探讨。方法采用竞争结合实验检测多肽P72与MHCⅡ类分子的亲合力;利用"两次攻击(two-hit)法"建立的动物模型研究P72对SEs的体内抑制活性。结果 P72不能与FITC-SEs有效竞争结合Raji细胞上的MHCⅡ类分子,P72对SEA、SEB和SEC致Balb/c小鼠休克效应具有显著的保护作用。结论 P72可能不是与MHC II类分子结合而产生的抑制作用,P72能够在体内抑制SEs的超抗原活性,其具体的抑制机制有待深入研究。 This study aims to investigate the mechanism of the broad-spectrum inhibitory activity of synthetic peptide P72 against SEA,SEB and SEC based on the previous research of competition assay and animal experiments.We detected the binding ability of the peptide P72 to MHC class Ⅱ molecules by competition assay and assessed the in vivo biological activity of peptide P72 against SEs by the "two-hit" animal model.The results indicated that the peptide P72 could not bind to MHC class Ⅱ molecules,while P72 can completely protect most of the Balb/c mice against toxic shock induced by SEA,SEB and SEC.In conclusion,our study demonstrates that the inhibitory activity of peptide P72 may not due to binding to MHCⅡ.And peptide P72 can inhibit the biological activity of SEs in vivo.But the exact mechanism of inhibitory activity of P72 still needs studies.
出处 《免疫学杂志》 CAS CSCD 北大核心 2012年第5期403-407,共5页 Immunological Journal
关键词 葡萄球菌肠毒素 超抗原 合成多肽 Staphylococcal Enterotoxin Superantigen Synthetic peptide
  • 相关文献

参考文献3

二级参考文献15

  • 1McCormick JK, Yarwood jM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update [J]. Annu Rev Microbiol, 2001, 55:77- 104.
  • 2Yarwood JM, Leung DY, Schlievert PM. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome [ J ]. FEMS Microbiol Lett, 2000, 192(1): 1-7.
  • 3Bunikowski R, Mielke ME, Skarabis H, et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis [ J ]. J Allergy Clin Immunol, 2000, 105(4) : 814- 819.
  • 4Eriksson A, Holm SE, Norgren M. Identification of domains involved in superantigenicity of streptococcal pyrogenic exotoxin F (SpeF)[J]. Microb Pathog, 1998, 25(5): 279- 290.
  • 5Jett M, Neill R, Welch C, et al. Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin[J]. Infect Immun, 1994, 62(8) :3408 - 3415.
  • 6Kum WW, Laupland KB, Chow AW. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class Ⅱ binding, superantigenic activity, and lethality [ J ]. Can J Microbiol, 2000, 46(2) : 171 - 179.
  • 7Arad G, Hillman D, levy R, et al. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock [J]. J Leukoc Biol, 2001, 69(6): 921- 927.
  • 8Arad G, Hillman D, Levy R, et al Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide [ J ]. Immunol Lett, 2004, 91(2/3): 141- 145.
  • 9Visvanathan K, Charles A, Barman J, et al. Inhibition of bacterial superantigens by peptides and antibodies [J]. Infect Immun, 2001, 69(2): 875- 884.
  • 10Kaempfer R. Peptide antagonists of superantigen toxins [J]. Mol Divers, 2004, 8(2) : 113 - 120.

共引文献17

同被引文献38

  • 1Inoshima N, Wang Y, Bubeck Wardenburg J. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection[J]. J Invest Dermatol, 2012, 132(5): 1513-1516.
  • 2Buheck Wardenburg J, Bae T, Otto M, et al. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia[J]. Nat Med, 2007, 13(12): 1405-1406.
  • 3Loughman JA, Fritz SA, Storch GA, et al. Virulence gene expression in human community-acquired Staphylococcus aureus infection[J]. J Infect Dis, 2009, 199(3): 294-301.
  • 4Mediavilla JR, Chen L, Mathema B, et al. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA)[J]. Curr Opin Microbiol, 2012, 15(5): 588-595.
  • 5Labandeira Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia[J]. Science, 2007, 315(10): 1130- 1133.
  • 6Adhikari RP, Karauzum H, Sarwar J, et al. Novel structurally designed vaccine for S. aureus alpha- hemolysin: protection against bacteremia and pneumonia[J]. PLoS One, 2012, 7(6): e38567.
  • 7Fritz S, Hogan P, Hayek G, et al. Staphylococcus aureus colonization in children with community -associated Staphylococcus aureus skin infections and their household contacts[J]. Arch Pediatr Adolesc Med, 2012, 166(6): 551- 517.
  • 8Fritz SA, Garbutt J, Elward A, et al. Prevalence and risk factors for community-acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus colonization in children seen in a practice-based research network [J]. Pediatrics, 2008, 121(10): 1090-1098.
  • 9Naas T, Fortincau N, Spicg C, et al. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing panton-valention leukocidin in a French university hospital[J]. Hosp Infect, 2005, 61(4): 321-329.
  • 10Brown EL, Bowden MG, Bryson RS, et al. Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton -Valentine leukocidin[J]. Clin Vaccine Immunol, 2009, 16(1): 139-141.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部